Best Peptides for Anti-Aging: Evidence-Backed Ranking

No peptide has been proven to extend healthy human lifespan. A handful have meaningful evidence for specific aging-related endpoints — telomere maintenance, NAD+ depletion reversal, mitochondrial function, skin regeneration, senescent-cell clearance. This ranking is by evidence strength per endpoint, not by general "anti-aging" claims. For the structured combined protocol, see anti-aging peptide stack.

For the hub with all longevity peptides ranked by study count, see /peptides/category/anti-aging.

How we rank

By evidence quality at the relevant aging endpoint — not by general "anti-aging" promise. A compound with strong evidence for skin elasticity ranks above a compound with strong evidence for "feeling younger."

Tier 1 — Strong evidence for specific aging endpoints

1. NAD+ (and precursors: NMN, NR)

NAD+ is a coenzyme required for sirtuin function, PARP-mediated DNA repair, and mitochondrial energy production. NAD+ levels decline with age across tissues.

What's strong: Multiple human trials demonstrate that oral NMN, NR, and IV NAD+ raise measured NAD+ levels. Mitochondrial-function biomarkers improve. Some functional improvements have been demonstrated; some haven't.

Format: Oral NMN 500 mg daily, oral NR 300 mg daily, or IV NAD+ infusion (weekly to monthly).

NAD+ research profile.

2. GHK-Cu (topical especially)

Copper tripeptide with decades of skin-aging evidence base. Visible improvements in skin elasticity, fine-line depth, and dermal regeneration in 12-week trials.

What's strong: Topical use for skin endpoints. Combination with retinoids and sunscreen produces consistent results.

Format: Topical 1–3% serum 2× daily.

GHK-Cu research profile. Copper peptides guide.

3. Epitalon

Pineal tetrapeptide. Strongest telomerase-activation evidence among peptides used in research-use settings. Russian gerontology cohort data over 20+ years shows reduced age-adjusted mortality and improved age-related biomarkers in elderly populations dosed annually.

Important caveat: Russian gerontology methodology is less rigorous than Western Phase 2/3 trials. The consistent signal across multiple cohorts is meaningful but not conclusive.

Format: SC 5–10 mg daily for 10–20 days, annually or semi-annually.

Epitalon research profile.

Tier 2 — Mechanistically strong, evidence emerging

4. SS-31 (Elamipretide)

Cardiolipin-targeted mitochondrial protective peptide. Phase 2/3 trials in primary mitochondrial diseases show measurable functional improvements; longevity-specific data is animal-heavy.

Best for: Users with measured mitochondrial dysfunction or cardiovascular concerns.

SS-31 research profile.

5. Glutathione

Tripeptide (Cys-Gly-Glu); body's primary intracellular antioxidant. Levels decline with age. Liposomal oral and IV formulations raise intracellular levels measurably.

Format: Liposomal oral 500–1000 mg daily, or IV 1–2 g weekly.

Glutathione research profile.

6. FOXO4-DRI

Synthetic peptidomimetic designed as a senolytic — selectively triggers apoptosis in senescent cells via p53-FOXO4 interaction disruption. Mouse studies show measurable lifespan and healthspan improvements.

Important caveat: Almost no human data. High cost, limited availability. The senolytic class is conceptually promising but practically immature.

FOXO4-DRI research profile.

Tier 3 — Mechanistically interesting, weaker evidence

7. MOTS-c

Mitochondrial-derived peptide. Animal data on metabolic improvement and exercise capacity; human data limited. Mechanism overlap with SS-31.

MOTS-c research profile.

8. Humanin

Mitochondria-derived neuropeptide. Animal cognitive-aging data; limited human data.

Humanin research profile.

9. Bioregulator class (Pinealon, Cortagen, Vesugen, Livagen, etc.)

Khavinson-school short peptides. Russian gerontology evidence; Western validation limited.

/peptides/category/longevity for the full list.

What's NOT in this ranking

• HGH for off-label anti-aging. Not FDA-approved for that indication; illegal to prescribe for it in the US. Real cumulative risk at supraphysiologic doses.
• Stem-cell peptide therapy. Marketing-heavy, evidence-light. Outside the scope of this site.
• Generic "peptide therapy" packages that combine 5+ compounds without per-compound justification.

Practical guidance

A defensible 12-month anti-aging protocol is built from the Tier 1 + selective Tier 2 entries:

1. Daily: Topical GHK-Cu (skin-aging endpoint).
2. Daily: NMN 500 mg oral or NR 300 mg oral (NAD+ endpoint).
3. Annually or semi-annually: Epitalon 10-day course (telomerase + general aging).
4. As needed: SS-31 4-week cycle for mitochondrial focus; FOXO4-DRI courses if senescence-clearance is the priority and you've made peace with the limited human data.

For the structured stack-style protocol, see anti-aging peptide stack.

Realistic expectations

Even the strongest evidence supports specific biomarker improvements over multi-month windows. The compound effects are real but modest. No combination produces "stop aging" outcomes; the realistic frame is "modestly slow some measurable markers of aging while building good baseline lifestyle factors."

The single largest lever on aging in published evidence remains the foundational lifestyle factors — quality sleep, resistance training, cardiovascular fitness, social connection, sun protection, and diet. Peptides are at-the-margin additions, not replacements.

Where to go from here

• /peptides/category/anti-aging and /peptides/category/longevity — hubs with study-count rankings.
• Anti-aging peptide stack — structured 12-month protocol.
• Copper peptides guide, peptides for skin — skin-specific.
• Are peptides safe?, peptide side effects, peptide cycling — safety frame.

This is informational, not medical advice.